Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cell Source, Inc. (CLCS)
USD0.77
+0.02 (+2.44%)
US OTC Healthcare Biotechnology
Address
57 West 57th Street 10019
New York City, NY, US
New York City, NY, US
CEO
Itamar Shimrat
Website
cell-source.com
IPO
2014-05-01
CIK 1569340 ISIN US15114L1044
Description
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.77
+0.02 (+2.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.6K
Beta
-157.98
Float Shares
34.43M
Free Float %
76.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -3.61% | -2.15% | -16.67% | +110.53% | +60.00% | +233.33% | +133,233.33% | -46.67% | -15.79% | -8.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.77
Quality scores
Altman Z-Score
-345.06
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+11.8% Q4'24: +40.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'24: +17.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+10.8% Q4'24: +15.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.79× Q4'24: -6.70× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yair Reisner | 3.78M | 10.58% | 3.78M | — | 3.78M | — | IN | Israel | 2020-12-29 | ↗ |
| 2 | Darlene Soave | 3.59M | 9.90% | 3.59M | — | 3.59M | — | IN | United States | 2021-04-21 | ↗ |
| 3 | Yeda Research & Development Co., Ltd. | 3.12M | 9.70% | 3.16M | — | 3.16M | — | CO | Israel | 2020-11-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-10 | Verstraete George | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-09 | Soave Darlene | Director / 10% Owner | J-Other | A | Warrant (Option to buy) | 800,000 | 1.25 | 1.00M | 800,000 | — | ↗ |
| 2021-06-30 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 4,860 | 0.75 | 3.6K | 1,127,504 | — | ↗ |
| 2021-06-30 | Soave Darlene | Director / 10% Owner | J-Other | A | Common Stock | 59,507 | 0.75 | 44.6K | 174,434 | — | ↗ |
| 2021-06-30 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 19,440 | 0.75 | 14.6K | 4,408,184 | — | ↗ |
| 2021-06-30 | Brown Dennis M | Director | J-Other | A | Common Stock | 2,976 | 0.75 | 2.2K | 114,927 | — | ↗ |
| 2021-03-25 | Soave Darlene | — | — | D | Common Stock | 0 | 0.00 | — | 258,414 | — | ↗ |
| 2021-03-08 | SHIMRAT ITAMAR | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 750,000 | 1.00 | 750.0K | 750,000 | — | ↗ |
| 2021-03-02 | Soave Darlene | — | — | D | Warrant (right to buy) | 800,000 | 1.25 | 1.00M | 0 | — | ↗ |
| 2020-12-29 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 4,941 | 0.75 | 3.7K | 1,117,784 | — | ↗ |
| 2020-12-29 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 19,672 | 0.75 | 14.8K | 4,471,200 | — | ↗ |
| 2020-12-29 | Brown Dennis M | Director | J-Other | A | Common Stock | 3,025 | 0.75 | 2.3K | 111,951 | — | ↗ |
| 2020-08-20 | ZOLTY DAVID | Director | A-Award | A | Director Stock Option (Right to Buy) | 300,000 | 0.75 | 225.0K | 300,000 | — | ↗ |
| 2020-08-20 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | D-Return | D | Director Stock Option (Right to Buy) | 300,000 | 0.75 | 225.0K | 0 | — | ↗ |
| 2020-08-19 | Brown Dennis M | Director | A-Award | A | Director Stock Option (Right to Buy) | 450,000 | 0.75 | 337.5K | 450,000 | — | ↗ |
| 2020-06-30 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 4,887 | 0.75 | 3.7K | 1,112,843 | — | ↗ |
| 2020-06-30 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 19,547 | 0.75 | 14.7K | 4,451,438 | — | ↗ |
| 2020-06-30 | Brown Dennis M | Director | J-Other | A | Common Stock | 2,992 | 0.75 | 2.2K | 108,926 | — | ↗ |
| 2019-12-31 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 6,420 | 0.75 | 4.8K | 1,107,956 | — | ↗ |
| 2019-12-31 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 25,675 | 0.75 | 19.3K | 4,431,891 | — | ↗ |
| 2019-12-31 | Brown Dennis M | Director | J-Other | A | Common Stock | 5,934 | 0.75 | 4.5K | 105,934 | — | ↗ |
| 2019-08-13 | REISNER YAIR | — | — | D | Stock Options (right to buy) | 3,782,004 | 0.75 | 2.84M | 0 | — | ↗ |
| 2019-06-26 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 1,339 | 0.75 | 1.0K | 1,101,536 | — | ↗ |
| 2019-06-26 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 5,356 | 0.75 | 4.0K | 4,406,216 | — | ↗ |
| 2019-05-07 | ZOLTY DAVID | Director | A-Award | A | Series A Convertible Preferred Stock | 7,888 | 0.75 | 5.9K | 7,888 | — | ↗ |
| 2019-05-07 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 31,553 | 0.75 | 23.7K | 31,553 | — | ↗ |
| 2019-02-13 | Brown Dennis M | Director | A-Award | A | Series A Convertible Preferred Stock | 6,667 | 0.75 | 5.0K | 6,667 | — | ↗ |
| 2018-12-31 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 1,361 | 0.75 | 1.0K | 1,100,197 | — | ↗ |
| 2018-12-31 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 5,444 | 0.75 | 4.1K | 4,400,860 | — | ↗ |
| 2018-11-08 | Soave Darlene | — | — | D | Series A Convertible Preferred Stock | 1,333,340 | 0.75 | 1.00M | 0 | — | ↗ |
| 2018-08-21 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 1,668 | 0.75 | 1.3K | 1,098,836 | — | ↗ |
| 2018-08-21 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 6,672 | 0.75 | 5.0K | 4,395,416 | — | ↗ |
| 2017-12-04 | ZOLTY DAVID | Director | J-Other | A | Common Stock | 1,350 | 0.75 | 1.0K | 1,097,168 | — | ↗ |
| 2017-12-04 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | J-Other | A | Common Stock | 5,400 | 0.75 | 4.1K | 4,388,744 | — | ↗ |
| 2017-07-26 | ZOLTY DAVID | Director | A-Award | A | Series A Convertible Preferred Stock | 3,000 | 0.75 | 2.3K | 10,888 | — | ↗ |
| 2017-07-26 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | A-Award | A | Series A Convertible Preferred Stock | 12,000 | 0.75 | 9.0K | 43,553 | — | ↗ |
| 2015-11-09 | SHIMRAT ITAMAR | Director / Officer | A-Award | A | Warrants to Purchase Common Stock | 750,000 | 0.75 | 562.5K | 750,000 | — | ↗ |
| 2015-11-09 | Drucker Yoram | Director | A-Award | A | Warrants to Purchase Common Stock | 550,000 | 0.75 | 412.5K | 550,000 | — | ↗ |
| 2015-07-20 | ZOLTY DAVID | Director | A-Award | A | Warrants to Purchase Common Stock | 100,000 | 0.75 | 75.0K | 112,500 | — | ↗ |
| 2015-04-01 | ZOLTY DAVID | Director | — | D | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 1,095,818 | — | ↗ |
| 2015-04-01 | SHIMRAT ITAMAR | Director / Officer | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 575,004 | — | ↗ |
| 2015-04-01 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | — | I | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 4,383,344 | — | ↗ |
| 2015-04-01 | Drucker Yoram | Director | — | D | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 575,004 | — | ↗ |
| 2015-04-01 | Brown Dennis M | Director | — | D | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2014-06-30 | ZOLTY DAVID | Director | — | D | Warrant to purchase 12,500 shares of Common Stock | 12,500 | 0.75 | 9.4K | 0 | — | ↗ |
| 2014-06-30 | FRIEDMAN BENZION ABRAHAM | Director / 10% Owner | — | I | Warrant to purchase 50,000 shares of Common Stock | 50,000 | 0.75 | 37.5K | 0 | — | ↗ |
| 2014-06-30 | Brown Dennis M | Director | — | D | Warrant to purchase 100,000 shares of Common Stock | 100,000 | 0.75 | 75.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
45.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Itamar Shimrat | Chief Executive Officer, President & Chief Financial Officer | 211.3K | male |
| Dennis Brown | Executive Chairman | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLCS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
